Inês holds a PhD in Biomedical Sciences from the University of Lisbon, Portugal, where she specialized in blood vessel biology, blood stem cells, and cancer. Before that, she studied Cell and Molecular Biology at Universidade Nova de Lisboa and worked as a research fellow at Faculdade de Ciências e Tecnologias and Instituto Gulbenkian de Ciência. Inês currently works as a Managing Science Editor, striving to deliver the latest scientific advances to patient communities in a clear and accurate manner.
Following discussions with the U.S. Food and Drug Administration (FDA), MacroGenics is planning for a single-arm clinical trial that supports the approval of its investigational molecule flotetuzumab for the ... Read more
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Ryvu Therapeutics’ oral inhibitor SEL120 for treating people with acute myeloid leukemia (AML). In the U.S., ... Read more
Treatment with MacroGenics‘ investigational molecule flotetuzumab completely eliminated traces of cancer cells in a large proportion of heavily treated acute myeloid leukemia (AML) patients, data from a Phase 1/2 ... Read more
People with acute myeloid leukemia (AML) who are in complete remission after their first-line chemotherapy and not suitable for a stem cell transplant have significantly better survival outcomes if ... Read more
Pin It on Pinterest